您的位置: 首页 » 法律资料网 » 法律法规 »

黑龙江省地图编制出版管理办法

时间:2024-07-21 23:12:29 来源: 法律资料网 作者:法律资料网 阅读:9278
下载地址: 点击此处下载

黑龙江省地图编制出版管理办法

黑龙江省人民政府


黑龙江省地图编制出版管理办法

黑龙江省人民政府令
 (第12号)


  《黑龙江省地图编制出版管理办法》业经省人民政府同意,现予发布,自1998年6月1日起施行。

                              省长 田凤山
                           1998年5月6日

第一章 总 则
第一条 为了加强全省地图编制出版管理,保证地图编制出版质量,根据《中华人民共和国地图编制出版管理条例》(以下简称《条例》)及有关法律、法规,结合本省实际,制定本办法。
第二条 凡在本省行政区域内,从事地图编制、出版(展示)活动的单位和个人,均应当遵守本办法。
第三条 本办法所称地图,是指公开出版、发行的各种普通地图和专题地图,以及公开展示的非出版地图。包括各种纸质地图、电子地图、立体地图、图书报刊和广告影视中插附的地图、示意性地图及其他形式的地图。
第四条 省人民政府测绘行政主管部门负责管理全省地图编制和审核工作;省人民政府其他有关部门负责本部门专题地图的编制工作。省人民政府出版行政管理部门商省人民政府测绘行政主管部门,负责管理全省的地图出版工作。
行政公署和市人民政府测绘行政主管部门负责本行政区域内公开销售和展示的地图的监督管理工作。

第二章 地图编制管理
第五条 编制普通地图和需要直接测绘的专题地图,应当依法取得相应的测绘资格。
甲级测绘资格由省人民政府测绘行政主管部门初审后,报国务院测绘行政主管部门审批发证;乙级以下测绘资格由所在地行政公署、市测绘行政主管部门初审后,报省人民政府测绘行政主管部门审批发证。
第六条 在地图上绘制中华人民共和国国界线、省级行政区域界线、中国历史疆界和世界各国国界,应当遵守《条例》第六条、第七条的规定。
第七条 在地图上绘制市、县级行政区域界线,应当遵守下列规定:
(一)省人民政府已经划定界线的,或相邻市、县人民政府已经协商确定界线的,按照有关文件或协议确定的画法绘制。
(二)相邻市、县人民政府虽未就界线划分签定协议,但是双方地图上界线绘制一致,且无争议的,按双方地图上一致的界线画法绘制。
(三)相邻市、县人民政府,对界线划分有争议,并且双方地图上界线绘制不一致的,按照省人民政府测绘主管部门和省人民政府民政主管部门制定并报省人民政府批准的市、县级行政区域界线标准画法图绘制。
第八条 地图内容的表示,应当符合国家有关规定,不得泄露国家机密,不得损害国家和社会公共利益。
第九条 以地图为载体刊登广告的,应当符合有关广告法律、法规的规定。除广告外,禁止以任何名义向地图上标名的单位收取费用。

第三章 地图审核出版管理
第十条 出版各种地图以及展示绘有国界线和县级以上行政区域界线或示意性轮廓线的非出版地图,应当在地图印刷或展示前,将下列材料报省人民政府测绘行政主管部门审核。需报国务院测绘行政主管部门审核的,由省人民政府测绘行政主管部门转报。
(一)申请地图审核的函件;
(二)地图试制样图一式三份。其中彩色地图报彩色打样图,单色地图报原稿复印件,非出版的展示地图报原设计稿复制件;
(三)国务院出版行政管理部门批准的地图出版范围文件;
(四)送审普通地图和需要测绘的专题地图的,提供地图编制单位的测绘资格证书副本;
(五)送审刊登广告的地图的,提供广告经营许可证副本;
(六)送审地方性乡土教材插图和配套的地图、地图册的,提供省教育行政管理部门批准编制出版的文件;
(七)送审电子地图的,提供光(软)盘和与光(软)盘内容相同的纸质地图;
(八)送审专业性较强的专题地图的,提供有关行政主管部门就专业内容出具的审核批准函;
(九)编制地图所使用的地理底图,涉及他人著作权的,提供著作权人同意使用的书面证明。
省人民政府测绘行政主管部门根据需要,可以委托行政公署、市测绘行政主管部门审核。
第十一条 公开出版的地图由出版单位送审,展示非出版的地图由展示单位送审。
省内的出版单位与国外或香港、澳门、台湾地区的组织、个人合作出版的地图,由省内合作方送审。
第十二条 省人民政府测绘行政主管部门,应当自收到试制样图和有关资料之日起30日内将审核决定通知送审单位。逾期未通知的,视为同意出版或展示。需报国务院测绘行政主管部门或移送外省人民政府测绘行政主管部门审核的除外。
第十三条 普通地图应当由专门地图出版社出版,其他出版社不得出版。
各出版社、报社、杂志社,可以根据需要在图书、报刊中插附地图。
第十四条 出版社的年度或单项地图出版计划,应当经其主管部门审核批准,省人民政府出版行政主管部门审核同意后,报省人民政府测绘行政主管部门备案。
第十五条 地图出版物,必须按国家有关规定发行。持有密级的地图和内部地图不得以任何形式公开出版、发行、销售或展示。
第十六条 经审核同意出版的地图,应当在地图上载明省人民政府测绘行政主管部门发给的地图审核登记号。刊登广告的地图,还应当载明广告经营许可证号。
第十七条 出版地图,应当注明地图上国界线画法的依据资料及其来源。广告、商标、宣传画、电影电视画面中的示意地图除外。
第十八条 地图出版物印刷出版后10日内,送审单位应当将样本一式两份报省人民政府测绘行政主管部门备案。
第十九条 地图著作权受法律保护。未经地图著作权人许可任何单位和个人不得以任何方式使用其地图,著作权法律、行政法规另有规定的除外。

第四章 法律责任
第二十条 违反本办法规定,未取得相应测绘资格,擅自编制普通地图或需直接测绘的专题地图的,由省人民政府测绘行政主管部门依据《条例》第二十四条的规定责令停止编制活动,没收违法所得,可以并处违法所得一倍以下的罚款。
第二十一条 违反本办法规定,有下列行为之一者,由省人民政府测绘行政主管部门责令停止发行、销售、展示,对有关单位和个人给予下列处罚:
(一)地图印刷或者展示前未按照规定送审的,责令限期报审,并处以300元以上3000元以下的罚款;
(二)地图印刷或展示前未按照审核意见修改的,处以3000元以下的罚款;
(三)专题地图在印刷或展示前,未按规定送审的,责令限期报审,并处以300元以上4000元以下的罚款;
(四)地图上国界或市、县以上行政区域界线的绘制不符合国家和省有关规定的,处以3000元以上1万元以下的罚款;
(五)地图内容的表示不符合国家有关规定,造成严重后果的,处以5000元以上1万元以下的罚款。
第二十二条 违反本办法规定,公开出版、发行、销售、展示保密地图或内部地图的,由省人民政府测绘行政主管部门或行政公署、市测绘行政主管部门,责令停止出版、发行、销售、展示,没收全部地图和违法所得,可以并处1000元以上1万元以下的罚款。
第二十三条 测绘行政主管部门可以按有关法律、法规的规定,对违反本办法规定的单位和个人给予没收地图及违法所得的处罚。
第二十四条 违反本办法规定,未经批准,擅自从事地图出版活动或者超越经批准的地图出版范围出版地图的,由省人民政府出版行政管理部门责令停止违法行为,没收全部非法地图出版物和违法所得,可以并处违法所得5倍以上15倍以下的罚款。
第二十五条 地图送审单位弄虚作假,伪造证件或材料的,由省人民政府测绘行政主管部门给予警告,责令改正或撤销核准的地图审核登记号。地图已经出版的,按照本办法第二十四条规定给予处罚。
第二十六条 当事人对行政处罚决定不服的,可以在接到处罚决定书之日起15日内,依法申请行政复议或向人民法院提起诉讼。逾期不申请复议,也不提起诉讼,又不履行处罚决定的,由作出处罚决定的机关申请人民法院强制执行。
第二十七条 地图编制、出版管理人员弄虚作假,玩忽职守,徇私舞弊,构成犯罪的,依法追究刑事责任;尚不构成犯罪的由其所在单位或上级主管部门给予行政处分。

第五章 附 则
第二十八条 本办法由黑龙江省人民政府测绘行政主管部门负责解释。
第二十九条 本办法自1998年6月1日起施行。



1998年5月6日

Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


高等级公路建设同时敷设通信管道的管理规定

邮电部


高等级公路建设同时敷设通信管道的管理规定
1992年7月19日,邮电部

为了更好地实施交通部、邮电部(88)交计字458号“关于印发高等级公路与电信管孔建设相互配合问题会议纪要的通知”达到互惠互利,节省投资,提高效益的目的,特制定本规定。
一、各邮电管理局在确定与高等级公路建设的同时敷设通信管道项目时应考虑以下几点:
(一)公路建设与拟建设的光(电)缆同路由,而且建设期相近;
(二)在高等级公路上建设通信管道可使今后光(电)缆施工不受季节性的影响;
(三)有利于光(电)缆平时的安全;
(四)便于施工和日常维护;
(五)较多地降低光(电)缆的施工费用。
符合以上原则的项目,邮电部门应在规划、项目建议书、设计任务书、初步设计的各个阶段中与交通部门密切配合,互通信息,相互协调,积极争取在高等级公路建设时同步建设电信管道。
二、项目实施程序
(一)各邮电管理局将本规划期间开工的高等级公路和邮电需同时建设通信管道的计划报部计划司。计划内容为公路等级、建设的起始地点及沿途所经过的县级以上城市、公路里程、建设起始年、公路建设的进度安排及邮电部门建设通信管道的计划,包括管孔数量、长度、投资额等。
(二)计划司根据各省邮电管理局报来的材料,汇总平衡后,正式列入计划。
(三)各相关邮电管理局根据邮电部的计划,即可与公路管理部门签定在高等级公路上建设通信管道的合同,并将合同副本报部。在合同中应明确:邮电部门在高等级公路上投资建设的通信管道,邮电部门拥有资产所有权和使用权;由邮电部门负担的建设通信管道的费用和根据高等级公路的建设进度,邮电部门每年应支付的款额。
(四)邮电部在收到合同后,按邮电部确定的补助金额,在年度计划中予以下达。
三、资金补贴标准
根据邮电部(1992)84号文的精神,一级干线的施工费和管道建设由各相关邮电管理局负担。考虑到在高等级公路上建设通信管道,需要提前支付费用,且不立即产生经济效益的情况,邮电部对在高等级公路上建设通信管道采取资金补助的办法,即属一级干线的路段,邮电部每公里给予一万五千元补助,属二级干线的路段,由各相关邮电管理局自行负担。